	US 12,448,433 B2
	Human ApoB100 epitopes, methods and uses for modulating inflammatory responses, and treating adverse cardiovascular events, disease and atherosclerosis
Klaus Ley, La Jolla, CA (US); and Alessandro Sette, La Jolla, CA (US)
Assigned to LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY, La Jolla, CA (US)
Filed by LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY, La Jolla, CA (US)
Filed on Sep. 27, 2021, as Appl. No. 17/486,820.
Application 17/486,820 is a continuation of application No. 15/574,784, granted, now 11,130,798, previously published as PCT/US2016/032981, filed on May 18, 2016.
Claims priority of provisional application 62/163,841, filed on May 19, 2015.
Prior Publication US 2022/0259288 A1, Aug. 18, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/775 (2006.01); A61K 38/10 (2006.01); A61K 38/17 (2006.01); A61P 1/16 (2006.01); A61P 9/10 (2006.01); C07K 7/08 (2006.01); A61K 39/00 (2006.01); A61K 45/06 (2006.01)

CPC C07K 14/775 (2013.01) [A61K 38/10 (2013.01); A61K 38/1709 (2013.01); A61P 1/16 (2018.01); A61P 9/10 (2018.01); C07K 7/08 (2013.01); A61K 39/0005 (2013.01); A61K 2039/57 (2013.01); A61K 45/06 (2013.01)]

13 Claims

1. A peptide consisting of an amino acid sequence set forth in any one of SEQ ID NOs: 10, 11, 16, 17, 19 and 20, wherein the peptide binds to one or more major histocompatibility complex II (MHC-II) molecules.